Chiesi is hoping real world evidence will show its latest COPD triple therapy can help cut hospital admissions for the disease. Trimbow (beclometasone+formoterol+glycopyrronium) combines an ...
The FDA has started a priority review of Chiesi 's velmanase alfa, an enzyme replacement therapy for lysosomal storage disease (LSD) alpha-mannosidosis, with a decision expected in the first half ...
Chiesi UK & Ireland has published new research revealing significant gaps in the understanding and practice of inhaler use among UK asthma patients. The study published in the BMJ Open Respiratory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback